Abt-751 (BioDeep_00001871535)

   


代谢物信息卡片


ABT-751 (E7010)

化学式: C18H17N3O4S (371.09397220000005)
中文名称: ABT-751
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O
InChI: InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent

同义名列表

2 个代谢物同义名

ABT-751 (E7010); Abt-751



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Zhi Xu, Shi-Jia Zhao, Yi Liu. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry. 2019 Dec; 183(?):111700. doi: 10.1016/j.ejmech.2019.111700. [PMID: 31546197]
  • Hongtao Du, Shan Tian, Juncheng Chen, Hongling Gu, Na Li, Junru Wang. Synthesis and biological evaluation of N(9)-substituted harmine derivatives as potential anticancer agents. Bioorganic & medicinal chemistry letters. 2016 08; 26(16):4015-9. doi: 10.1016/j.bmcl.2016.06.087. [PMID: 27397495]
  • M Silver, A Rusk, B Phillips, E Beck, M Jankowski, J Philibert, K Hahn, E Hershey, E McKeegan, J Bauch, A Krivoshik, C Khanna. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma. Journal of veterinary internal medicine. 2012 Mar; 26(2):349-54. doi: 10.1111/j.1939-1676.2012.00892.x. [PMID: 22369215]
  • Charles M Rudin, Ann Mauer, Martin Smakal, Rosalyn Juergens, Stanislav Spelda, Michael Wertheim, Andrew Coates, Evelyn McKeegan, Peter Ansell, Xiangdong Zhou, Jane Qian, Rajendra Pradhan, Barry Dowell, Andrew Krivoshik, Gary Gordon. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Mar; 29(8):1075-82. doi: 10.1200/jco.2010.32.5944. [PMID: 21300929]
  • Elizabeth Fox, John M Maris, Susan L Cohn, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Diane Medina, Hao Xiong, Andrew Krivoshik, Brigitte Widemann, Peter C Adamson, Frank M Balis. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer chemotherapy and pharmacology. 2010 Sep; 66(4):737-43. doi: 10.1007/s00280-009-1218-z. [PMID: 20044751]
  • Yanping Luo, Vincent P Hradil, David J Frost, Saul H Rosenberg, Gary B Gordon, Sherry J Morgan, Gerard D Gagne, Bryan F Cox, Stephen K Tahir, Gerard B Fox. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anti-cancer drugs. 2009 Jul; 20(6):483-92. doi: 10.1097/cad.0b013e32832c0acf. [PMID: 19398903]
  • Steve Y Cho, Elizabeth Fox, Cynthia McCully, Joy Bauch, Kennan Marsh, Frank M Balis. Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. Cancer chemotherapy and pharmacology. 2007 Sep; 60(4):563-7. doi: 10.1007/s00280-006-0402-7. [PMID: 17187251]
  • Christopher L Morton, Edward G Favours, Kimberly S Mercer, Claire R Boltz, Jeri Carol Crumpton, Chandra Tucker, Catherine A Billups, Peter J Houghton. Evaluation of ABT-751 against childhood cancer models in vivo. Investigational new drugs. 2007 Aug; 25(4):285-95. doi: 10.1007/s10637-007-9042-y. [PMID: 17384918]
  • Michelle A Rudek, Ming Zhao, Ping He, Wells A Messersmith, Sharyn D Baker. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. Journal of pharmaceutical and biomedical analysis. 2006 Sep; 42(2):253-60. doi: 10.1016/j.jpba.2006.04.010. [PMID: 16765012]
  • Kenneth R Hande, Anne Hagey, Jordan Berlin, Yingna Cai, Kysa Meek, Hiro Kobayashi, A Craig Lockhart, Diane Medina, Jeffrey Sosman, Gary B Gordon, Mace L Rothenberg. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 May; 12(9):2834-40. doi: 10.1158/1078-0432.ccr-05-2159. [PMID: 16675578]
  • K Yamamoto, K Noda, A Yoshimura, M Fukuoka, K Furuse, H Niitani. Phase I study of E7010. Cancer chemotherapy and pharmacology. 1998; 42(2):127-34. doi: 10.1007/s002800050795. [PMID: 9654112]
  • N Koyanagi, T Nagasu, F Fujita, T Watanabe, K Tsukahara, Y Funahashi, M Fujita, T Taguchi, H Yoshino, K Kitoh. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer research. 1994 Apr; 54(7):1702-6. doi: NULL. [PMID: 8137285]